NCT05225415Phase 2Completed

Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies

Study sponsor: Cognition Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-11-25Actual
Enrollment · participants130Actual
Source updated2026-03-12Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Safety and Tolerability of CT1812. After: Measure: Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview